Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy
Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy
复制标题
DOI：
10.21873/anticanres.14835
复制
发表时间：
2021-02-01
影响因子：
2
通讯作者：
Akimoto, Tetsuo
中科院分区：
文献类型：
--
作者：
Nakamura, Masaki;Kageyama, Shun-Ichiro;Akimoto, Tetsuo
背景/目的：探讨游离细胞DNA （cfDNA）在少转移患者中的应用价值。患者和方法：本研究包括在单一机构接受立体定向体放疗或质子束治疗转移性病变消融照射的少转移性结直肠癌（CRC）患者。从预处理患者的血浆中提取cfDNA，并通过下一代测序分析基因突变。根据基因突变、克隆性或等位基因频率对无进展生存期（PFS）进行统计学比较。结果：共分析20例患者。在以下基因中检测到突变；TP53(45%)、APC(40%)、喀斯特(15%),PIK3CA(15%)、NFI(5%)、乳腺癌易感基因1(5%)、ERBB2(5%)、FBXW7(5%)、设备(10%),和极品(10%)。基因突变多克隆的患者PFS较差（p=0.07）。在7例转移部位为肺的患者中，未检测cfDNA的患者的PFS明显优于cfDNA的患者（p=0.02）。结论：cfDNA谱可作为少转移性结直肠癌患者消融放疗后早期复发的预测工具。
Background/Aim: To investigate the usefulness of cell-free DNA (cfDNA) in patients with oligometastasis. Patients and Methods: This study included oligometastatic colorectal cancer (CRC) patients who underwent ablative irradiation using stereotactic body radiotherapy or proton beam therapy for metastatic lesions at a single institution. cfDNA was purled from the plasma of pretreated patients and gene mutations were analyzed by next-generation sequencing. Progression-free survival (PFS) was statistically compared according to gene mutation, clonality or allele frequency. Results: A total of 20 patients were analyzed. Mutations were detected in the following genes; TP53 (45%), APC (40%), KRAS (15%), PIK3CA (15%), NFI (5%), BRCA1 (5%), ERBB2 (5%), FBXW7 (5%), KIT (10%), and HRAS (10%). Patients with multi-clonality of gene mutation showed tendency for poor PFS (p=0.07). Among 7 patients whose metastatic site was the lung, those with no cfDNA detected had significantly better PFS than those with cfDNA (p=0.02). Conclusion: cfDNA profiles could be predictive tools for early recurrence of oligometastatic CRC patients after ablative radiotherapy.